The company's strong cash position gives investors confidence in the gene-editing stock.
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Morning Overview on MSN
Harvard team uses CRISPR to silence extra chromosome 21 in lab
A research team led by geneticist Jeannie Lee at Harvard Medical School, cell biologist Jeanne Lawrence at UMass Chan Medical ...
CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...
Intellia Therapeutics will seek U.S. approval for its in vivo CRISPR therapy lonvo-z after a Phase III trial in hereditary angioedema showed an 87% reduction in attacks versus placebo. The one-time ...
Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024 ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results